

# CONFERENCE AGENDA

---

8:00-8:30 Continental Breakfast, Registration, and Check In

---

8:30-9:00

WELCOME AND KEYNOTE ADDRESS: HEPATITIS C AND VULNERABLE POPULATIONS  
JAY BUTLER, MD

Objective: Participants will be able to identify populations at increased risk for hepatitis C infection and who should be tested.

---

9:00-9:30

HEPATITIS C IN ALASKA'S PRISONS AND JAILS  
ROBERT LAWRENCE, MD

Objective: Participants will be able to describe the hepatitis C virus and understand the epidemiology of Hepatitis C infection in Alaska Department of Corrections

---

9:30-10:00

ALL YOU WANT TO KNOW ABOUT THE HEPATITIS C VIRUS  
BRIAN MCMAHON, MD

Objective: Participants will be able to describe the hepatitis C virus and understand the epidemiology of Hepatitis C infection

---

10:00-10:15

**Break**

---

10:15-11:00

PATIENT EVALUATION AND TREATMENT READINESS  
LISA TOWNSHEND-BULSON, ANP

Objective: Participants will be able to evaluate patients for treatment readiness.

Objective: Participants will be able to describe the importance of staging liver fibrosis prior to treatment.

---

11:00-11:45

MEDICATION BASICS

**Annette Hewitt, ANP**

Objective: Participants will be able to identify commonly used medications in the treatment of Hepatitis C.

Objective: Participants will be able to describe an appropriate treatment regimen for a treatment naïve, noncirrhotic patient.

---

11:45-12:15

PRIOR AUTHORIZATION, MEDICATION ASSISTANCE PROGRAM, AND MEDICAID

**Lisa Meyers, Prior Authorization Specialist**

Objective: Participants will be able to describe the insurance prior authorization process.

Objective: Participants will be able to identify at least one medication assistance program for hepatitis C treatment.

---

12:15-12:30

MORNING SESSIONS SPEAKER PANEL: Q&A

---

12:30-1:00

**Lunch Provided**

---

1:00-1:30

HCV TREATMENT IN PRIMARY CARE

**Scott Miller, PA-C; Benjamin Turman, PA-C; Carol Indorf, RN; Lisa Meyers**

Objective: By the end of this learning event participants will be able to describe tools for management of the care of HCV patients and how to implement them.

---

1:30-2:00

STARTING A SYRINGE SERVICES PROGRAM AT A PRIMARY CARE FACILITY

**Jessica Rienstra, RN**

Objective: By the end of this learning event participants will be able to describe best practices for screening and treating of HCV in persons who inject drugs (PWID)

---

2:00-3:30

ECHO: CASE PRESENTATIONS AND TX RECOMMENDATIONS

**Training participants are invited to present patients and receive treatment recommendations**

Objective: By the end of this learning event participants will be able to describe best practices for screening and treating HCV

---

3:30-4:00

DISCUSSION, QUESTIONS, WRAPUP